Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

102.89
+1.291.27%
Post-market: 102.890.00000.00%19:31 EDT
Volume:650.45K
Turnover:66.78M
Market Cap:5.08B
PE:-17.83
High:103.83
Open:101.13
Low:100.00
Close:101.60
Loading ...

Axsome Therapeutics Price Target Maintained With a $200.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

RBC Trims Price Target on Axsome Therapeutics to $190 From $192, Keeps Outperform Rating

MT Newswires Live
·
03 Apr

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Zacks
·
03 Apr

Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680

Zacks
·
02 Apr

Deutsche Bank Adjusts Axsome Therapeutics Price Target to $187 From $200, Maintains Buy Rating

MT Newswires Live
·
02 Apr

Axsome Therapeutics Inc. : Deutsche Bank Cuts Target Price to $187 From $200

THOMSON REUTERS
·
02 Apr

Why Shares of Axsome Therapeutics Slumped Today

Motley Fool
·
02 Apr

Axsome Therapeutics Shares Down 4.5% After Co's Depression Treatment Fails to Meet Main Goal of Late-Stage Study

THOMSON REUTERS
·
01 Apr

Axsome Therapeutics Price Target Maintained With a $153.00/Share by Needham

Dow Jones
·
01 Apr

BUZZ-Axsome falls on depression drug's trial setback

Reuters
·
01 Apr

Axsome Therapeutics Shares Down 2.5% Premarket After Co's Depression Treatment Fails to Meet Main Goal of Late-Stage Study

THOMSON REUTERS
·
01 Apr

Axsome's depression treatment fails to meet main goal of late-stage study

Reuters
·
01 Apr

Axsome Therapeutics: in Overall Patient Population, Study Did Not Show Statistically Significant Change on Madrs Total Score VS Placebo

THOMSON REUTERS
·
01 Apr

Axsome Therapeutics Announces Topline Results of Paradigm Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (Mdd) With and Without Excessive Daytime Sleepiness (Eds)

THOMSON REUTERS
·
01 Apr

Axsome Therapeutics: Results Support Continued Development in Mdd With Concomitant Eds; Phase 3 Trial Planned in 2025

THOMSON REUTERS
·
01 Apr

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

GlobeNewswire
·
01 Apr

Axsome Therapeutics Is Maintained at Outperform by Mizuho

Dow Jones
·
27 Mar

Axsome Therapeutics Inc : Mizuho Raises Target Price to $216 From $212

THOMSON REUTERS
·
27 Mar

Mizuho Securities Adjusts Axsome Therapeutics Price Target to $216 From $212, Maintains Outperform Rating

MT Newswires Live
·
26 Mar

Buy Rating Affirmed for Axsome Therapeutics Amid Promising ADHD Treatment Results and Strategic Market Positioning

TIPRANKS
·
26 Mar